Breaking News

Does Race Influence Prostate Cancer Treatment in the Military?

June 29, 2021 • 10:07 am CDT
(Vax Before Cancer)

The AC Journals published an Original Article on June 29, 2021, focused on prostate cancer (CaP) treatment. The study authors aimed to assess the role of race-related treatment benefit in access to CaP treatment in a single-payer population.

The study used the Veterans Health Administration (VHA) Corporate Data Warehouse identified 35,427 men to perform a retrospective cohort study of veterans diagnosed with low- or intermediate-risk CaP between 2011 and 2017.

When they controlled for covariates, Black men at a VA facility had 1.05 times the odds of receiving treatment compared to non-Black men, and high-treatment-benefit men had 1.4 times the odds of receiving treatment compared to those in the low-treatment-benefit group.

And the interaction of race and treatment benefit was significant. Black men in the high-treatment-benefit category were less likely to receive treatment than non-Black men in the same treatment category (odds ratio, 0.89; P < .001).

The study author's conclusion was: Although race does appear to influence the receipt of definitive treatment in the VHA, this relationship varies in the context of the patient's treatment benefit, with Black men receiving less definitive treatment in high-benefit situations.

And, the influence of patient race at high treatment benefit levels invites further investigation into the driving forces behind this persistent disparity in this consequential group.

'Prostate cancer is the second most common cancer among men (skin cancer), but it can often be treated successfully. If you have prostate cancer or are close to someone who does, knowing what to expect can help you cope. Here you can find out all about prostate cancer, including risk factors, symptoms, how it is found, and how it is treated,' says

The U.S. National Cancer Institute estimates that 248,000 men will be diagnosed with prostate cancer in 2021, most in its earliest stages.